- Home
- BBIO vs ESNT Comparison
BBIO vs ESNT Comparison
Compare BBIO & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- ESNT
- Stock Information
- Founded
- BBIO 2015
- ESNT 2008
- Country
- BBIO United States
- ESNT Bermuda
- Employees
- BBIO N/A
- ESNT N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- ESNT Property-Casualty Insurers
- Sector
- BBIO Health Care
- ESNT Finance
- Exchange
- BBIO Nasdaq
- ESNT Nasdaq
- Market Cap
- BBIO 10.4B
- ESNT N/A
- IPO Year
- BBIO 2019
- ESNT 2013
- Fundamental
- Price
- BBIO $62.64
- ESNT $60.57
- Analyst Decision
- BBIO Strong Buy
- ESNT Buy
- Analyst Count
- BBIO 18
- ESNT 6
- Target Price
- BBIO $73.89
- ESNT $65.67
- AVG Volume (30 Days)
- BBIO 2.7M
- ESNT 623.5K
- Earning Date
- BBIO 10-29-2025
- ESNT 11-07-2025
- Dividend Yield
- BBIO N/A
- ESNT 2.05%
- EPS Growth
- BBIO N/A
- ESNT N/A
- EPS
- BBIO N/A
- ESNT 6.85
- Revenue
- BBIO $353,780,000.00
- ESNT $1,268,306,000.00
- Revenue This Year
- BBIO $115.12
- ESNT $4.27
- Revenue Next Year
- BBIO $65.29
- ESNT $1.54
- P/E Ratio
- BBIO N/A
- ESNT $8.84
- Revenue Growth
- BBIO 62.46
- ESNT 5.28
- 52 Week Low
- BBIO $21.72
- ESNT $51.61
- 52 Week High
- BBIO $69.48
- ESNT $65.90
- Technical
- Relative Strength Index (RSI)
- BBIO 64.23
- ESNT 47.89
- Support Level
- BBIO $52.75
- ESNT $59.21
- Resistance Level
- BBIO $69.48
- ESNT $60.98
- Average True Range (ATR)
- BBIO 2.86
- ESNT 1.09
- MACD
- BBIO 0.81
- ESNT 0.10
- Stochastic Oscillator
- BBIO 59.12
- ESNT 64.33
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.